Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile.

Antimicrobial agents and chemotherapy - 1 Oct 2025

Lai Yen-Ting, Dingens Adam S, DeMouth Megan, Helmold Hait Sabrina, O'Dell Sijy, Schon Arne, Olia Adam S, Wang Tao, Shrader Hannah R, Lovelace Sarah E, Pegu Amarendra, Doria-Rose Nicole A, Mascola John R, Bloom Jesse D, Kwong Peter D

Abstract excerpt

BMS-818251, a fostemsavir analog, is a next-generation HIV-1 attachment inhibitor with enhanced potency and a similar resistance profile. By using ex vivo viral outgrowth assays with HIV+ donor samples, we demonstrate here that BMS-818251 exhibits superior viral suppression compared to temsavir, the active form of fostemsavir. To map potential resistance pathways, we employed deep mutational scanning and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to env Gene Products, Human Immunodeficiency Virus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp120

Share to HIV Infections

Share to Neutralization Tests

Share to Organophosphates

Share to Piperazines

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 40863730
DOI: 10.1128/aac.01910-24
PMCID: PMC12486810

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile.PMID 40863730Read ↗

Comprehensive mapping of the virus and host factors that guide the paths of HIV-1 escape from a therapeutic.Semantic proximity Read ↗

Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtideSemantic proximity Read ↗

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.Semantic proximity Read ↗

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.Semantic proximity Read ↗

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.Semantic proximity Read ↗

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068Semantic proximity Read ↗

In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043Semantic proximity Read ↗

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.Semantic proximity Read ↗

Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavirSemantic proximity Read ↗

Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.Semantic proximity Read ↗

HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications.Semantic proximity Read ↗

Structural and Mechanistic Basis of F227C-Mediated Hypersusceptibility to Islatravir in HIV-1 Reverse TranscriptaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.